Is the Future of Skinny Labelling to be Reconsidered? - McDermott

GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Overview


Chris Bruno will speak on a panel for LSPN Connect on the topic of “GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?” Discussion will include an overview of the role of skinny labelling in the US FDA’s regulation of drug products and the implications of the recent GSK v Teva ruling on patent strategies for brand and generic drug manufacturers.

Click here for more information and to register.

Dig Deeper

Boston, MA / Speaking Engagements / May 8-9, 2024

LSPN North America – Spring 2024

Chicago, IL / Speaking Engagements / March 20 - 21, 2024

WIPR Summit: Charting the Course for Global IP Excellence

New York, NY / McDermott Event / January 30, 2024

Raising Capital in 2024: Navigating New Opportunities

Tokyo, Japan / McDermott Event / January 17, 2024

2024 McDermott International Seminar in Japan

Get In Touch